Sebclair™ cream, the number
one treatment for seborrheic (PRONOUNCED: seb-o-REE-ik) dermatitis (SD) in America
was launched on 17 January 2016 by A.Menarini Singapore Pte Ltd, a subsidiary
of the leading bio-pharmaceutical company in Italy at the Hilton Kuala Lumpur. Being
the latest addition to Menarini’s range of innovative and clinically-proven dermatitis
treatments, Sebclair™ is the first NON-STEROIDAL ANTI-INFLAMMATORY TOPICAL
MEDICAL DEVICE CREAM (TMD) INDICATED FOR SEBORRHEIC DERMATITIS (SD) to be
introduced in Malaysia.
(From left to right) Prof Dr Giuseppe Micali, Dr Henry Foong
Boon Bee (President of Persatuan
Dermatologi Malaysia) and Dr Steven Januar Kusmanto showcasing Sebclair™ to
doctors and members of the media.
SD is a long-term chronic inflammatory
skin disorder affecting areas where sebaceous glands (oil glands) are present
in high density and are most active. SD is a common skin disorder, affecting 2-10%
of the general population. In a published study in the Chinese Journal of Dermatovenerology in 2008, Asian adolescents ages 12-20 years are affected by SD; Macao (2.66%),
Guangzhou (2.85%), Malaysia (17.16%) and Indonesia (26.45%). SD causes scaling,
erythema (reddening) and sometimes pruritus (itching) of the scalp, nasolabial
folds (nose area), eyebrows, eyelids, face and centre of the chest. It appears
most often in adults ages 30-60 and in infants within the first three months of
life as ‘cradle cap’. Mild SD may appear as uncontrolled dandruff.
Often underdiagnosed, SD
does not affect your overall health, but it can be uncomfortable and cause
embarrassment. This skin disorder may need many repeated treatments before the
symptoms go away. There is no cure for SD, but there is a wide range of
products available to treat its signs and symptoms.
Speaking at the launch was
Prof Dr Giuseppe Micali, Head of Dermatology Department and Dermatologist
Residency Program Director, University of Catania, Italy, who highlighted the
limitations of the current treatment for SD.
“In my experience, when there’s
an inflammation, topical anti-fungals are not very effective. So, we need a
combination of therapies. For the past years, there’s a need for a new
treatment. There needs to be non-prescription agents, such as non-steroidal
anti-inflammatory and antifungal that represents a promising approach in the
management of some mild to moderate forms of SD, as demonstrated by in vitro
and in vivo studies,” he said.
Sebclair™ cream is approved
for use in Malaysia as a medical device cream and is indicated for the
treatment of SD in both infants and adults. It is a non-steroidal cream that
has demonstrated both anti-inflammatory and antifungal properties. Sebclair™
for treatment of SD has comparable efficacy and fewer relapses than a
low-potency topical corticosteroid. Sebclair™ has been recommended as a
first-line treatment for seborrheic flares and for long-term maintenance in the
newly published Asian SD Consensus Guideline Handbook. It has the potential to
replace both anti-inflammatory and antifungal treatments in SD patients.
Sebclair™ contains several
active ingredients to offer a complete approach to treat SD. Shea butter acts
an emollient that helps protect and restore the skin barrier. Propylene glycol and
acifructol complex acts as a keratolytic agent to soften and shed the scaly
outer layer of the skin. Sebclair™ cream has been shown to work within days in
babies diagnosed with cradle cap as presented in real patient case studies by
Malaysian paediatricians during the launch.
To address the redness and
inflammation, Sebclair™ cream offers an arsenal of anti-inflammatory and
anti-itch agents: glycyrrhetinic acid (licorice root extract), bisabolol
(chamomile extract) and allantoin. To boost the immunity of the skin cells,
Sebclair™ comes with a plethora of antioxidants namely vitamins C and E, vitis
vinifera (grapevine) and telmesteine.
As the yeast-like fungi Malassezia sp. are commonly found among
SD patients, Sebclair™ also contains piroctone olamine, an antimycotic agent to
destroy or prevent the growth of this fungi.
Sebclair™ has no
restrictions on patient’s age, duration of use or areas of application. It is well-tolerated
to be applied on the face too. Sebclair™ does not contain steroids or immune-suppressing
agents. Sebclair™ is a topical medical device cream that is effective as a single
therapy (monotherapy) in the treatment of mild to moderate SD. Prof Micali
shared that it is possible that the effectiveness of the cream is due to a synergistic
effect of piroctone olamine (antimycotic action), propylene glycol (keratolytic
action), allantoin and glycyrrhetinic acid (anti-inflammatory action).
Also present at the launch
were Dr Steven Januar Kusmanto, Regional
Therapeutic Area Manager of Menarini Asia Pacific; Dr Henry Foong, the President of Persatuan Dermatologi Malaysia
(PDM); and a panel of leading dermatologists and paediatricians in the
country.
No comments:
Post a Comment